Clinical Trial Update: A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Bemosubaiabimab plus Anlotinib with radiotherapy and chemotherapy for oligometastatic esophageal cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Bemosubaiabimab

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Esophageal Cancer | Phase 2 | Status: RECRUITING